US stock · Healthcare sector · Biotechnology
C
Coherus BioSciences, Inc.
CHRS
NASDAQ6.00
USD
+0.10
(+1.69%)
Market Closed
-2.13P/E
8Forward P/E
-0.10P/E to S&P500
477.659MMarket CAP
- -Div Yield
Upcoming Earnings
3 May-8 May
Shares Short
2/28/23
9.84M
Short % of Float
15.55%
Short % of Shares Outs.
12.37%
% Held by Insiders
2.03%
% Held by Institutions
105.00%
Beta
0.92
PEG Ratio
0.15
52w. high/low
14.11/5.58
Avg. Daily Volume
1.30M
Return %
Stock
S&P 500
1 year
(48.38)
(9.05)
3 years
(55.67)
50.26
5 years
(48.30)
38.50
Scale: |
High
Low
14.44
4.93
7.00
0.57
6.68
0.45
6.91
2.84
5.06
2.29
7.44
4.59
17.31
12.27
38.10
15.50
31.98
12.04
29.59
8.05
20.66
8.39
23.91
8.32
23.03
10.86
22.22
12.21
16.48
5.58
10.99
5.71
Currency: USD
- -
- -
- -
- -
- -
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
- -
- -
- -
- -
- -
0.11
0.19
3.80
0.81
4.54
0.03
- -
5.11
6.66
4.13
2.67
Earnings per share
- -
- -
- -
- -
- -
(1.83)
(3.65)
(10.64)
(6.01)
(3.04)
(4.48)
(3.22)
1.29
1.85
(3.63)
(3.69)
FCF per share
- -
- -
- -
- -
- -
(1.11)
1.02
(3.27)
(3.08)
(6.18)
(3.86)
(2.46)
0.22
2.06
(0.49)
(3.05)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
0.10
0.03
0.35
0.17
0.16
0.09
0.01
0.19
0.10
0.02
0.03
Book Value per sh.
- -
- -
- -
- -
- -
0.51
(2.89)
8.16
(0.17)
0.49
0.60
(0.59)
1.51
3.93
1.24
(1.74)
Comm.Shares outs.
- -
- -
- -
- -
- -
18
15
8
37
42
53
65
70
71
79
79
Avg. annual P/E ratio
- -
- -
- -
- -
- -
(3.3)
- -
(1.4)
(4.4)
(7.3)
(3.8)
(4.2)
13.5
9.7
(4.4)
(2.7)
P/E to S&P500
- -
- -
- -
- -
- -
(0.2)
- -
(0.1)
(0.2)
(0.3)
(0.2)
(0.2)
0.6
0.3
(0.1)
(0.1)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
2
3
31
30
190
2
- -
356
476
327
211
Operating margin
- -
- -
- -
- -
- -
(2,028.3)%
(1,308.4)%
(207.9)%
(729.2)%
(61.0)%
(14,918.8)%
(Infinity)%
30.3%
32.9%
(80.8)%
(121.7)%
Depreciation (m)
- -
- -
- -
- -
- -
0
0
1
2
3
3
3
3
3
3
4
Net profit (m)
- -
- -
- -
- -
- -
(33)
(54)
(87)
(223)
(127)
(238)
(209)
90
132
(287)
(292)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.2%
2.6%
- -
- -
Net profit margin
- -
- -
- -
- -
- -
(1,738.7)%
(1,949.7)%
(280.1)%
(743.2)%
(67.0)%
(15,306.6)%
(Infinity)%
25.2%
27.8%
(87.9)%
(138.2)%
Working capital (m)
- -
- -
- -
- -
- -
14
(8)
127
91
105
117
51
228
622
437
278
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
100
102
103
178
404
416
231
Equity (m)
- -
- -
- -
- -
- -
9
(42)
67
(6)
21
32
(39)
105
281
98
(137)
ROIC
- -
- -
- -
- -
- -
(206.2)%
773.0%
(61.4)%
(208.5)%
(96.8)%
(168.7)%
(301.6)%
36.4%
22.0%
(51.4)%
(75.8)%
Return on capital
- -
- -
- -
- -
- -
(118.7)%
(101.9)%
(44.4)%
(104.7)%
(66.4)%
(139.5)%
(200.7)%
27.0%
18.6%
(38.9)%
(53.9)%
Return on equity
- -
- -
- -
- -
- -
(359.2)%
126.6%
(130.4)%
3,596.9%
(620.3)%
(748.4)%
542.5%
85.4%
47.1%
(293.8)%
212.3%
Plowback ratio
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(52.7)%
- -
- -
- -
Capital Structure
6 Mar · 2023 | Q4
All numbers in millions
Total liabilities
$ 618
Total assets
$ 481
Long-term debt
$ 231
Cash and equiv.
$ 64
Goodwill
$ - -
Retained earnings
$ (1,342)
Common stock
78
Enterprise Value
$ 645
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
541
417
192
Receivables
157
123
110
Inventory
44
38
115
Other
25
(99)
(478)
Current assets
767
602
417
Acc. Payable
15
16
12
Debt due
- -
3
- -
Other
130
146
127
Current liabilities
146
165
139
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(35.37)%
- -
- -
Cash flow
522.72%
284.28%
141.08%
Earnings
1.62%
(102.79)%
(17.84)%
Dividends
- -
- -
- -
Book value
(240.62)%
(127.86)%
(163.92)%
Insider Trading
Type
Shares
Date
Mcmichael Bryan J
Award
12,500
01/20/23
Lanfear Dennis M
Award
86,250
01/20/23
Stilwell Mcdavid
Award
40,000
01/20/23
Vexler Vladimir
Award
40,000
01/20/23
Vexler Vladimir
InKind
3,602
01/11/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
116
136
114
110
476
2021
83
88
83
73
327
2022
60
60
45
45
211
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.50
0.83
0.39
0.14
1.85
2021
(2.19)
(0.38)
(0.49)
(0.58)
(3.63)
2022
(1.22)
(0.63)
(1.10)
(0.75)
(3.69)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Dennis M. Lanfear
Full-time employees:
376
City:
Redwood City
Address:
333 Twin Dolphin Drive
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Recent News
· 15 Feb, 2022 · The Wall Street Journal
· 16 Oct, 2021 · The Wall Street Journal
· 13 Jul, 2021 · The Wall Street Journal